Bright Minds Biosciences Inc. (CSE:DRUG)
Canada
· Delayed Price · Currency is CAD | Market Cap | 327.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.07M |
| Shares Out | 7.04M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 725 |
| Average Volume | 333 |
| Open | 46.11 |
| Previous Close | 45.24 |
| Day's Range | 46.00 - 46.99 |
| 52-Week Range | 1.30 - 108.00 |
| Beta | 1.19 |
| RSI | 53.84 |
| Earnings Date | May 14, 2025 |
About Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboratio... [Read more]
Financial Performance
Financial StatementsNews
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. DRUG, an epilepsy drug developer.
Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside
Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. (NASDAQ: DRUG), an epilepsy drug developer . The company’s lead product, BMB-101, is a novel scaffold 5-HT2C Gq-prote...
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selec...
Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025
COMMODORE CAPITAL LP's Strategic Acquisition in Bright Minds Biosciences Inc
COMMODORE CAPITAL LP's Strategic Acquisition in Bright Minds Biosciences Inc
Sio Capital Management, LLC Acquires Significant Stake in Bright Minds Biosciences Inc
Sio Capital Management, LLC Acquires Significant Stake in Bright Minds Biosciences Inc
JANUS HENDERSON GROUP PLC Acquires Shares in Bright Minds Biosciences Inc
JANUS HENDERSON GROUP PLC Acquires Shares in Bright Minds Biosciences Inc
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101
Bright Minds Biosciences names Stephen Collins as chief medical officer
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Brig...
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that further to its news release of ...
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most...
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
LONDON--(BUSINESS WIRE)---- $DRUG #Nasdaq--Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demons...
Cormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences Shares
Cormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences Shares
What's Going On With Bright Minds Biosciences Stock?
Bright Minds Biosciences Inc (NASDAQ: DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly N...
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing no...
Monster insider trading alert for this penny stock that rallied $3,700% in a week
This week, the stock market witnessed a peculiar price movement involving biotech firm Bright Minds Biosciences (NASDAQ: DRUG), which skyrocketed … Continue reading The post Monster insider trading al...
What's Going On With Bright Minds Biosciences Stock Friday?
Bright Minds Biosciences shares are moving ... Full story available on Benzinga.com
Bright Minds rebounds after $35M private placement
Bright Minds Biosciences (DRUG) stock surged by ~48% in premarket trading after the company announced a $35M private placement mainly for R&D. Read more here.
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
Perceptive Advisors LLC Acquires New Stake in Bright Minds Biosciences Inc
Perceptive Advisors LLC Acquires New Stake in Bright Minds Biosciences Inc
Bright Minds rally ends as psychedelic stocks extend volatility
Bright Minds Biosciences (DRUG) stock fell 29% following over 15-fold ris in the previous session as psychedelic drug developers experienced volatility. Read more here.
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Bioscience...
Why did this penny stock skyrocket 1,500% in a day
When most major equities recorded notable losses, the share price of biotech company Bright Minds Biosciences (NASDAQ: DRUG) experienced a … Continue reading The post Why did this penny stock skyrocke...